Somewhere inside a federal nutrition lab in Beltsville, Maryland, researchers handed adults with obesity a simple assignment: drink a glass of tomato-soy juice every day for four weeks. The juice was not exotic. It was made from two of the most widely available plant foods on the planet, blended to concentrate lycopene from tomatoes and isoflavones from soy. By the end of the trial, blood draws showed that specific pro-inflammatory cytokines, including interleukin-6 (IL-6), had dropped significantly compared with a control period when the same participants drank ordinary low-carotenoid tomato juice.
The results, published in June 2026 in the journal Nutrients, arrive at a moment when the scale of the obesity crisis has forced a rethink about which interventions are worth pursuing. A 2024 analysis in The Lancet estimated that more than one billion people worldwide now live with obesity. Pharmaceutical treatments like GLP-1 receptor agonists have shown dramatic results, but they cost thousands of dollars a year and remain out of reach for most of the global population. A shelf-stable juice made from tomatoes and soybeans would cost pennies per serving.
What the USDA trial actually measured
The study, registered on ClinicalTrials.gov and sponsored by the USDA’s Beltsville Human Nutrition Research Center, used a crossover design. That means every participant went through both conditions: four weeks on the high-lycopene tomato-soy juice, then four weeks on the control juice (or vice versa), with a washout period in between. Because each person served as their own control, the design filters out the individual differences in gut bacteria, baseline inflammation, and habitual diet that plague most nutrition studies.
After the tomato-soy arm, researchers found statistically significant reductions in circulating pro-inflammatory cytokines compared with the control period. The team also ran untargeted urinary metabolomics, a technique that maps hundreds of small molecules the body produces as it processes food. That metabolomics layer is important because it can reveal whether the juice’s anti-inflammatory effects trace to specific metabolic pathways or simply reflect a broader dietary shift.
An earlier human study using the same or a closely related USDA formulation had already established that the juice’s plant compounds do not just pass through the gut unabsorbed. That trial, conducted in men with prostate cancer, showed dose-responsive increases in plasma and urinary levels of carotenoids and isoflavones, confirming bioavailability. Without that proof of uptake, any downstream claim about inflammation would rest on much weaker ground.
Why tomatoes and soy together
Neither ingredient is new to inflammation research. Peer-reviewed trials have shown that tomato juice on its own can reduce markers of systemic inflammation in overweight and obese women, and that it can lower inflammatory adipokines (signaling molecules released by fat tissue) independently of any change in body weight. The tomato matrix, rich in lycopene, beta-carotene, and other carotenoids, appears to carry anti-inflammatory potential on its own.
Soy isoflavones, particularly genistein and daidzein, act through different but potentially complementary mechanisms. They interact with estrogen receptors and modulate signaling cascades like NF-kB, a master switch for inflammatory gene expression. The USDA team’s hypothesis was that combining the two in a single beverage would produce a broader anti-inflammatory effect than either food alone. The cytokine data from the new trial are consistent with that hypothesis, though they do not definitively prove synergy.
Preclinical work in rodent models of chronic pancreatitis has also found that a soy-tomato enriched diet reduced inflammation and disease severity, hinting at applications beyond obesity. Animal data cannot substitute for human trials, but they add biological plausibility to the idea that these two food matrices interact in meaningful ways.
What the study does not tell us
Four weeks is a short window. The published paper and the ClinicalTrials.gov record do not describe what happened to cytokine levels after participants stopped drinking the juice. If the anti-inflammatory benefits fade within days of stopping, the practical implications are very different from a durable effect that outlasts the intervention.
The trial was also conducted at a single research center with a relatively small number of participants. Crossover designs are statistically efficient, but the population was not large or diverse enough to reveal how factors like age, sex, ethnicity, or baseline diet might modify the response. Replication in bigger, more varied cohorts is a necessary next step before any dietary guideline could follow.
Compliance data and adverse-event logs have not been posted publicly on the trial registry. Without that information, it is difficult to know how consistently participants consumed the juice each day or whether anyone experienced side effects, even minor digestive discomfort. The full cytokine dataset and exact p-values are available in the published paper, but the raw metabolomics data have not been released as a standalone dataset, limiting independent reanalysis.
Perhaps the most important caveat: the study measured biomarkers, not clinical outcomes. Lower IL-6 levels correlate with reduced risk of cardiovascular disease, type 2 diabetes, and certain cancers, but correlation is not causation. No one in this trial was tracked for heart attacks, hospital admissions, or long-term weight change. The juice lowered molecules associated with disease risk. Whether it actually prevents disease remains unproven.
What this means for people trying to manage inflammation
This study does not position a tomato-soy drink as a cure for obesity or a substitute for established treatments like calorie management, physical activity, or medications such as GLP-1 agonists when clinically indicated. What it does suggest is that a specific, phytochemical-rich beverage made from inexpensive, widely available ingredients can modestly improve short-term inflammatory profiles in people with obesity.
For anyone wondering about practical details: the juice used in the trial was a research-grade formulation, not a commercial product currently on store shelves. However, the ingredients (tomato juice and soy protein or soy milk) are easy to find, and the concept is straightforward enough that food scientists or even home cooks could approximate it. The key variables are lycopene concentration and isoflavone dose, both of which would need to be in the range used by the USDA team to expect similar results.
Drinking a glass of V8 is not the same thing. Standard commercial tomato juices vary widely in lycopene content and contain no soy isoflavones. The specificity of the formulation matters, and that is a point the researchers emphasize.
Where the research goes from here
The path forward is clear but not fast. Larger trials in diverse populations, longer intervention periods, transparent sharing of anonymized cytokine and metabolomics data, and eventually studies that track whether regular consumption translates into fewer clinical events. The USDA team has laid a credible foundation: a registered, controlled, crossover human trial with biomarker confirmation and metabolomics depth. That is more rigor than most dietary intervention studies achieve.
But rigor at a small scale is still small scale. The tomato-soy juice sits in a familiar spot in nutrition science: mechanistically plausible, statistically significant in a controlled setting, and far from proven in the real world. What makes it worth watching is the combination of low cost, high scalability, and a biological rationale that holds up across multiple lines of evidence. In a global obesity crisis where the most effective drugs remain unaffordable for the majority of people who need them, even a modest, food-based tool that reliably dials down inflammation would matter.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
